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Markov model was constructed to analyse CHB patients’ life
expectancy (LE) of no antiviral treatment versus 18-month, 36-
month, and unrestricted duration of lamivudine treatment, and
their associated reimbursement cost from Taiwan National
Health Insurance (TNHI) perspective. Disease progression, 
clinical effectiveness and patient population information were
obtained from systematic review of published studies. Costs of
medication, diagnostics, physician’s fees, and hospitalization
were included. Incremental cost-effectiveness ratios (ICERs)
compared to disease progression without antiviral treatment
were derived. The annual cost of lamivudine treatment was
based on a 10% recruitment rate from 120,000 eligible 30-year-
old CHB patients. All costs and health outcomes were discounted
at 3%. RESULTS: CHB without antiviral treatment results in LE
loss of 21.7 years for 30-year-old CHB patients. Lamivudine
used for 18-months, 36-months, and unrestricted treatment
duration could increase LE by 2.5, 4.0, and 5.1 years respec-
tively; continuing treatment in patients with cirrhosis could
increase LE by 10.2 years. Expected lifetime costs to the TNHI
for no antiviral treatment were US$12,854 per patient. Incre-
mental costs of using lamivudine for 18-month, 36-month, and
unrestricted duration were US$697, US$1031 and US$1278
respectively. ICERs for 18-month, 36-month, and unrestricted
were US$575.7, US$542.5, and US$530.3; and US$1820.4 for
treating cirrhotic patients. Expected maximal annual budget for
lamivudine was US$13.0m, US$15.3m, and US$15.3m for 18-
month, 36-month, and unrestricted respectively; and US$32.3m
for continuing treatment in cirrhotic patients. CONCLUSIONS:
CHB results in marked LE loss to patients. Lamivudine treat-
ment notably improves LE. The effectiveness of lamivudine
increased with increased treatment duration and when contin-
ued in cirrhotic patients. Long-term antiviral treatment of CHB
with lamivudine is a cost effective strategy in Taiwan with a man-
ageable impact on budgets.
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FOR PATIENTS WITH PERSISTENT DYSPEPSIA IN THE UK
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OBJECTIVES: To assess the cost-effectiveness of three tests for
HP detection in adults and develop decision analysis models to
compare “test—no test” strategies for the treatment of persistent
dyspepsia. METHODS: Two decision analytic models were con-
structed and analysed from the perspective of the health service.
The ﬁrst model was a simple decision tree of three types of HP
test, allowing for true and false test results, with the ‘number of
true outcomes’ as the measure of effectiveness. Tests considered
were the serological test, the C-urea breath test and the mono-
clonal faecal antigen test. The second model was based on pub-
lished guidelines for managing dyspepsia and procedures in
secondary care. Measures of effectiveness for the second model
include numbers in each end state, number of endoscopies per-
formed, and number of HP eradication treatments given inap-
propriately and the extent of wasted resources consumed. Data
used to furnish the models were gathered from the literature and
available published costs. RESULTS: The monoclonal faecal
antigen test was the most cost effective solution with an ICER
of £2 per additional true outcome, but was highly dependent on
the sensitivity and speciﬁcity of the serological test. The stool test
and the breath test either dominate or are relatively cost effec-
tive in relation to the serological test unless the speciﬁcity of the
serological test exceeds 0.93. The stool test either dominates or
is relatively cost effective in relation to serological test up to a
cost of £18.67 per stool test. Preliminary results from the second
model suggest that the decision is highly dependent on values
attached to the variables in the model, especially in relation to
costs of treatment and costs associated with malignancy. CON-
CLUSION: In the UK, the faecal antigen test is a cost effective
solution to testing for HP in dyspepsia patients.
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TREATMENT OF CIRRHOSIS OF THE LIVER WITH SILYMARIN,
A COST-EFFECTIVENESS ANALYSIS, BASED ON GERMAN
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Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, Germany
OBJECTIVES: To clarify whether the therapy of liver cirrhosis
with silymarin shows a higher cost-effectiveness than a treatment
without from of the third party payerxs perspective.
METHODS: To calculate the incremental cost-effectiveness
based upon a clinical study, the liver-related mortality rates of
patients with liver cirrhosis after four years, treated with or
without silymarin, were compared. Adverse effects (AE) and
adverse drug reactions (ADR) were also be considered. Com-
parative parameters were costs, effectiveness and tolerability of
both alternatives. Costs were generated by the drug therapy of
liver cirrhosis, medical care, and treatments of AE and ADR,
which were derived from previous studies and portrayed in a
core-model. The calculation of the model was performed by util-
ising the program DATA Professional. Two sensitivity-analyses
were conducted. RESULTS: For liver-related mortality total costs
of €5467 for silymarin and €3333 without silymarin were gen-
erated. The effectiveness-adjusted costs were calculated at €5970
for silymarin and €4009 for treatment without silymarin. This
entails that for the longer survival time of 9.12 months, incre-
mental costs of €1961 were calculated per silymarin patient.
However, as an effect, less AEs occurred and longer survival of
patients could be achieved with silymarin treatment of liver cir-
rhosis. CONCLUSION: With silymarin treatment of liver cir-
rhosis less AEs and longer survival of patients could be achieved.
By considering the concept of prolonged life, cost amounting to
€2580 was estimated per life year gained (lyg).
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OBJECTIVES: Peginterferon alfa-2b (12KD)/ribavirin (PEG2b)
has been shown to produce a higher rate of sustained virologi-
cal response (SVR) than non-pegylated combination therapy
(non-PEG) in CHC, but the cost effectiveness of this improved
efﬁcacy has not been assessed in Brazil. METHODS: We devel-
oped a Markov model to describe the clinical history of CHC in
which the cohorts of hepatitis C virus (HCV) patients received
PEG2B or non-PEG for either 48 or 24 weeks according to geno-
type and liver histology and were followed for their expected life-
time. The reference patient was a 30-year-old male with CHC
without cirrhosis. The SVRs to PEG2B and non-PEG were 48%
and 34% for HCV genotype 1 and 88% and 80% for non-1,
respectively. Quality of life for each health state was based on
literature. Costs for each health state were based on three Delphi
panels, one with hepatologists, one with intensivists and another
with oncologists. Costs in 2004 reais and beneﬁts were dis-
counted at 3%. RESULTS: In HCV genotype 1, PEG2B increases
life expectancy (LY) by 1.79 years and quality adjusted life
expectancy (QALY) by 0.82 years compared to non-PEG. The
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incremental cost per QALY gained is 21.074 reais. In HCV non-
1 genotype patients, PEG2B increases LY by 1.02 and QALY by
0.47 years in comparison to non-PEG. The incremental cost per
QALY gained is 15.057 reais. The weighted average incremen-
tal cost-effectiveness ratio, using population-based HCV geno-
type distribution estimates, for all genotypes was 17.832 per
QALY. CONCLUSIONS: Peginterferon alfa-2b (12KD)/
ribavirin are a cost-effective therapy for treatment of naive adults
with CHC compared with standard interferon alfa-2b/ribavirin,
regardless of HCV genotype.
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OBJECTIVES: To assess the cost-effectiveness of two treatment
strategies for reﬂux esophagitis (RE) in Finland: acute treatment
with esomeprazole 40mgqd followed by maintenance treatment
with 20mgqd, or acute treatment with pantoprazole 40mgqd
followed by maintenance treatment with 20mgqd. METHODS:
A decision analysis model was developed to compare the two
treatment strategies with regard to direct medical costs (drugs,
physician visits, investigations, procedures) and productivity
costs (absence from work and reduced productivity while at
work) using a 7-month time horizon. Probabilities for treatment
success were based on results from a large multinational, ran-
domised, double-blind clinical study of up to 8 weeks acute (n
= 3170) and 6 months maintenance (n = 2766) treatment of RE.
The proportion of patients with treatment success and an esti-
mated number of weeks with symptoms of gastro-esophageal
reﬂux disease (GERD) were used as effectiveness measures. Sen-
sitivity analyses were made by using upper and lower 95% con-
ﬁdence limits of the clinical study results, as well as by changing
patient management assumptions. RESULTS: The proportion of
patients with treatment success, deﬁned as healed RE within 8
weeks acute treatment and no relapse during subsequent main-
tenance treatment, was 83.4% and 69.6% for esomeprazole and
pantoprazole, respectively (i.e. an absolute difference of 13.8%).
This corresponded to 1.1 weeks less with GERD per patient by
using esomeprazole. In the base case analysis, the mean estimated
direct medical cost per patient was slightly lower for the
esomeprazole strategy (€33) and the estimated productivity loss
per patient was considerably lower for the esomeprazole strat-
egy (€114). Sensitivity analyses supported robustness of main
ﬁndings. CONCLUSION: The esomeprazole treatment strategy
was found to be cost-effective compared with the pantoprazole
treatment strategy, since esomeprazole provides better effective-
ness and savings in work productivity costs at similar or lower
direct medical costs.
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OBJECTIVES: A recent study has shown that 48 weeks treat-
ment with peginterferon alfa-2a (40KD) (PEGASYS) compared
with lamivudine leads to improved efﬁcacy in patients with
HBeAg-positive CHB. However, the cost effectiveness of 
peginterferon alfa-2a compared with lamivudine has not been
assessed. The current analysis was designed to assess the net
health consequences, costs and cost-effectiveness of 48 weeks of
peginterferon alfa-2a for the treatment of patients with HBeAg-
positive CHB, compared with shorter term (48 weeks) and
longer term (4 years) lamivudine treatment. METHODS: A cost-
utility analysis from a payer perspective using a state-transition
Markov model simulating the natural history of CHB. Clinical
inputs were taken from a randomized trial comparing peginter-
feron alfa-2a and lamivudine for the treatment of HBeAg-
positive CHB. A reference cohort of patients with mean age of
32 years and HBeAg-positive disease was used. Life expectancy,
quality-adjusted life years (QALY), lifetime direct health care
costs, and incremental cost-effectiveness ratios (ICERs) were 
estimated. RESULTS: Treatment with peginterferon alfa-2a 
compared with lamivudine (for 48 weeks) resulted in higher 
total costs, but more QALYs gained, yielding an ICER of
£8820/QALY gained. The ICER comparing the two treatments
does not exceed £15,400/QALY gained despite variation in each
parameter used in the analysis. In the analysis comparing 48
weeks of treatment with peginterferon alfa-2a versus 4 years of
treatment with lamivudine, the ICER was £10,100/QALY
gained. CONCLUSIONS: Deﬁned 48 weeks treatment with
peginterferon alfa-2a (40KD) (PEGASYS) compared with either
short-term or long-term lamivudine treatment in HBeAg-positive
patients offers life expectancy beneﬁts for cost effectiveness
ratios that are well below the commonly accepted cost-
effectiveness threshold in the UK.
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The two inﬂammatory bowel diseases (IBD), Ulcerative colitis
CD and Crohn’s disease UC are chronic relapsing diseases. As
the major part of the health care costs of IBD consists of hospi-
talizations and surgery, there is a great potential for novel ther-
apies to reduce costs and improve quality of life (QoL) if they
could reduce the relapse rate and maintain patients in remission.
A novel treatment option in these patients is the Granulocyte and
monocyte/macrophage apheresis (Adacolumn®). OBJECTIVES:
To estimate the cost-effectiveness of treating (CD) and (UC)
patients with Adacolumn® aphaeresis compared to standard
treatment. METHODS: We developed a Markov model for the
treatment of UC and CD. The model and our cost-effectiveness
application for CD and UC is based on four data sources: (a) an
uncontrolled clinical study of the ﬁrst 100 patients treated with
Adacolumn® apheresis for IBD in clinical practice [The Scandi-
navian study], (b) a cohort of 147 IBD patients treated with 
usual care from Denmark [Danish Crohn Colitis Database-
Copenhagen County)] including 1 304 patient years (c) prices of
health care and pharmaceuticals from Sweden, (d) and QALY
data from literature. RESULTS: Surgical operations and days in
hospital were reduced by %90 cent. The cost per QALY gained
by treating patients for three years with Adacolumn® is
US$19,015 for UC and US$70,142 for CD, respectively. CON-
CLUSION: The comparison between the usual care treatment
and the Adacolumn® treatment is based on the matching of two
cohorts. Our results will be compared with forthcoming data
from a randomized clinical trial. Compared to usual care Ada-
